ADP050-ABC
/ Alector
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 07, 2025
Recent Clinical Updates
(GlobeNewswire)
- "The global, randomized, double-blind, placebo-controlled PROGRESS-AD Phase 2 clinical trial of AL101/GSK4527226 in early Alzheimer’s disease (AD) is ongoing, with enrollment completed in April 2025 and trial completion expected in 2026....Alector is currently evaluating potential candidates and continues to target clinical entry for ADP037-ABC and ADP050-ABC in 2026, pending resource allocation, lead candidate selection, and the results of preclinical studies."
New trial • Trial completion date • Alzheimer's Disease • Gaucher Disease • Lewy Body Disease • Parkinson's Disease
1 to 1
Of
1
Go to page
1